Pharma / Biotech

Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson's Disease.

Icon for Springer Icon for PubMed Central Related Articles

Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson’s Disease.

Eur J Drug Metab Pharmacokinet. 2020 Feb;45(1):41-49

Authors: Saqlain M, Alam M, Rönnegård L, Westin J

BACKGROUND AND OBJECTIVES: Levodopa concentration in patients with Parkinson’s disease is frequently modelled with ordinary differential equations (ODEs). Here, we investigate a pharmacokinetic model of plasma levodopa concentration in patients with Parkinson’s disease by introducing stochasticity to separate the intra-individual variability into measurement and system noise, and to account for auto-correlated errors. We also investigate whether the induced stochasticity provides a better fit than the ODE approach.
METHODS: In this study, a system noise variable is added to the pharmacokinetic model for duodenal levodopa/carbidopa gel (LCIG) infusion described by three ODEs through a standard Wiener process, leading to a stochastic differential equations (SDE) model. The R package population stochastic modelling (PSM) was used for model fitting with data from previous studies for modelling plasma levodopa concentration and parameter estimation. First, the diffusion scale parameter (σw), measurement noise variance, and bioavailability are estimated with the SDE model. Second, σw is fixed to certain values from 0 to 1 and bioavailability is estimated. Cross-validation was performed to compare the average root mean square errors (RMSE) of predicted plasma levodopa concentration.
RESULTS: Both the ODE and the SDE models estimated bioavailability to be approximately 75%. The SDE model converged at different values of σw that were significantly different from zero. The average RMSE for the ODE model was 0.313, and the lowest average RMSE for the SDE model was 0.297 when σw was fixed to 0.9, and these two values are significantly different.
CONCLUSIONS: The SDE model provided a better fit for LCIG plasma levodopa concentration by approximately 5.5% in terms of mean percentage change of RMSE.

PMID: 31595429 [PubMed – indexed for MEDLINE]

Source link

Related posts

Revisited: Assessing the in vivo data on low/no-calorie sweeteners and the gut microbiota.


FDA Grants New Indication for Recarbrio for HABP/VABP


Identification of solubility-limited absorption of oral anticancer drugs using PBPK modeling based on rat PK and its relevance to human.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World